Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product ...

Apellis reported a net loss of $92.2 million for the first quarter of 2025 compared to a net loss of $66.4 million for the same period in 2024. Cash. As of March 31, 2025, Apellis had $358.4 million ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve ...

The FDA has approved a dihydroergotamine-based nasal powder for the acute treatment of migraine with or without aura in ...

On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...